Clinical Trial Update: INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update shows INCB000928 is being studied as a monotherapy or in combination with ruxolitinib for anemia due to myeloproliferative disorders, incl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Myelofibrosis
• Myelofibrosis Post-essential Thrombocythemia
• Myelofibrosis Post-polycythemia Vera

Drugs mentioned

• INCB000928
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Anemia, Post-essential Thrombocythemia Myelofibrosis | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING